1. Kathleen Giacomini, Mark J. Ratain, Michiaki Kubo, Naoyuki Kamatani, and Yusuke Nakamura NIH Pharmacogenomics Research Network III & RIKEN Center for Genomic Medicine Alliance, International Collaboration for Genomewide Association Studies PGRNIII-CGM Investigators in San Francisco 2009 Using genomewide approaches, identify genetic variants that contribute to individual responses to medicines, including rare and dangerous side effects. Publish results that will help clinicians optimize the safety and effectiveness of drugs for each patient. Introduction of PGRNIII-CGM Alliance Riken Center for Genomic Medicine (CGM) A component of the RIKEN Yokohama Institute, Japan established to develop high-throughput services for SNP analysis detect human gene variation in common diseases and medication responses. Pharmacogenomics Research Network (PGRN) A research group consortium funded through the NIH that conducts studies on variation in human genes relevant to drug disposition and action Pharmacogenomics research network in USA RIKEN CGM in JAPAN PG Research Network Goals of PGRNIII-CGM Alliance Genomewide Association (GWA) studies Biological/ pharmacologic mechanism Pharmacogenomic Studies Patients Genomewide Markers Identify mutant and polymorphic genes Controls Adverse Reaction ACE Inhibitor Angioedema Drug Induced Cardiac Arrhythmias Few pharmacogenomic studies of drug response/ toxicity, Jan 2009 Standard process for GWA studies Human subjects approval by USA-PGRN and RIKEN-CGM Careful collection of clinical samples with PGRNIII-CGM SOPs Plating and transferring DNA samples from PGRNIII site to CGM site Quality of DNA samples assessment and genotyping with Illumina 610 Quad by CGM Analysis of genotype and phenotype data Submission of the data and SOPs to dbGaP Anti-Cancer SSRI Anti- Depressants Cardiopulmonary Drugs Antiviral Process for starting GWA studies Call for proposals: twice a year Proposals reviewed by PGRN Coordinating Committee Proposals reviewed and selected by RIKEN CGM Team Acknowledgements These collaborative projects are supported by NIH grant GM61390 and the RIKEN Center for Genomic Medicine. The study is part of the NIH Pharmacogenomics Research Network-RIKEN Center for Genomic Medicine Global Alliance. CALGB 40101 is supported by NIH Grant CA31946. Conclusions PGRNIII-CGM is a powerful international collaboration between NIH-PGRN and Riken-CGM which will facilitate research discoveries of genetic/genomic factors contributing to drug effects and adverse reactions contribute to the development of personalized medicines directly benefit the healthcare of global populations Summary of our collaborations 1) An international collaboration in pharmacogenomics has been established with a focus on GWAS. 2) 18 Studies have been approved and are currently in various stages of implementation. 4 projects have either submitted or planned manuscripts 6 projects are analyzing their genotyping data 8 projects are collecting DNA samples for their GWA studies. 3) The data generated by the alliance is publicly available through dbGaP to benefit other scientists. 4) A new round of applications will be due in September. 18 PGRNIII-CGM Collaborative Studies Underway